Aarkstore – GRDSdata – Subscription to industry data from across more than 100 industries and 90 countries

Summary

“GRDSdata portal is a leading source of global industry information“. This interactive platform provides you with unlimited and immediate access to invaluable market data from across more than 100 industries and around 90 countries. Get instant access – wherever and whenever – to the most up-to-date market data. Gain a clear perspective on the actual market situation, trends, and future outlook for the industries that interest you. Benchmark different countries and product segments against each other, and use the data and graphs directly in your own presentations.

The industry data helps you find answers to such key questions as:

– What is the current market size for your product of interest globally and in different countries?

– How are the markets divided into different product segments?

– How are the overall market and different product segments growing?

– How are the markets predicted to develop in the future?

– What is the market potential between different countries and product segments?

Among the many business-critical reasons to subscribe include:

– Gaining a deep insight into the historical development, current market situation, on-going trends, and future outlook of the markets

– Tracking industry trends and identifying market opportunities

– Planning and developing marketing, market-entry, market expansion, and other business strategies by identifying the key market trends and prospects

– Saving time and money with the readily accessible key market data included in the platform. The market data is clearly presented and can be easily incorporated into presentations, internal reports, etc.

The main industries currently covered in GRDSdata include, among others: automotive, aerospace and transportation, chemicals, clothing and textiles, construction and mining, consumer goods, electronics, food and beverages, glass, machinery and equipment, manufacturing, materials, medical devices, metals, packaging, paper and pulp, plastics and rubber, pharmaceuticals, printing, and wood.

This premium subscription service offers an invaluable resource for industry executives, marketing, sales and product managers, analysts, and other industry experts looking for reliable industry data in a readily accessible and clearly presented format.

Subscription is a single user license. Subscription period is one year. For multi user licenses, please contact the sales representative.

Browse complete Report on:

http://www.aarkstore.com/business-services/52401/grdsdata-subscription-to-industry-data-from-across-more-than-100-industries-and-90-countries

For more Market research Report: http://www.aarkstore.com/market-research-reports-categories.html

Contact Details:

Aarkstore Enterprise
Phone: +91 9987295242 / 022-27564953
Email: enquiry@aarkstore.com
Our Website: http://www.aarkstore.com
Our Blog : http://www.aarkstore.com/blog/
Latest News : http://www.aarkstore.com/news
conference: http://conference.aarkstore.com/

Aarkstore – The Cancer Drugs & Treatments Market – Data, Analysis & Forecasts to 2023

Summary

GMR Data forecast that the global cancer drugs and treatments market will reach $143.7bn by 2023. GMR Data’s latest report The Cancer Drugs & Treatments Market – Data, Analysis & Forecasts to 2023’ explains just how this market will experience growth over the medium and long term. The report also highlights forecast for the next 5 and 10 years, so that you and your company can make specific long term plans. Don’t let your competitors get the head-start on you, order this report today.

Have you seen the recent news on Cancer Drugs?

– Merck’s new cancer drug kept more than 4 of 5 melanoma patients alive for a year

– Biopharma Alliances will be needed For Cancer Drugs in the cost conscious future – Forbes

– EU approval for Bayer’s prostate cancer drug

– Sanofi ditches late-stage bone marrow cancer drug

The Anti-cancer treatment market is already worth $77.4bn (GMR Data) and continues to be one of the largest and fastest growing areas for new drug development – can you afford not to be involved? Should you and your company be capturing a greater market share?

Essential facts examined in this report

1) Across 2013, 15 new molecular entities were approved by the FDA; out of which seven were for Oncology.

2) Currently targeted therapies dominate the oncology pipeline, followed by chemotherapy.

3) Immunotherapy drugs are gaining increasing amounts of attention due to fewer expected side effects.

Only by ordering this in-depth exclusive report will you have full access to the unique findings. This information is not available anywhere else. Find full details of these approved drugs alongside key cancer drugs in their testing phases in this new GMR Data report.

Discover exactly what the industry leaders are doing TODAY –

Within GMR Data’s The Cancer Drugs & Treatments Market – Data, Analysis & Forecasts to 2023’ we analyse the key cancer drugs and treatments in the market currently and how they will perform across the next decade.

Our study focuses on the individual revenues of the top 25 anti-cancer agents. With variable patents and the threat of generics, how will these key cancer drugs fare across the next decade? – ONLY THIS UNIQUE REPORT WILL TELL YOU

Rituxan
Herceptin
Avastin
Gleevec
Revlimid
Alimta
Velcade

PLUS – In-depth country analysis – Discover which countries and regions will drive the oncology drugs market to 2023?

The US spent $322bn on healthcare in 2011, GMR Data estimate that the US spent $31.8bn in the oncology market in 2012, capturing 40.5% of the market. 2nd to the US was Japan; spending $8.9bn in 2012, capturing 11.2%. The European mainstays of the pharmaceutical sector; the UK, Germany, France, Spain & Italy equated to 25% of the global oncology market in 2012.

But how will these country’s markets develop?

Exclusive Industry sourced information, not available anywhere else

As well as primary and secondary research sources, GMR Data have interviewed leading cancer specialists within big pharma, R&D, wholesalers, distributors, marketeers and key clinical organisations. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field

Browse complete Report on:

http://www.aarkstore.com/healthcare/67272/the-cancer-drugs-treatments-market-data-analysis-forecasts

For More Related Market Research Reports click here: Pharmaceuticals & Healthcare Market Research Reports

About Aarkstore.Com

Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on Market Research Reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.

Contact Details:

Aarkstore – Ophthalmic Drugs; Data, Analysis and Forecasts to 2024

Summary

Which ophthalmic drugs lead the market in 2013? Will the same drugs be as successful in 2018? How will this landscape change across the next 10 years? Which trial drugs are likely to make an impact? Only one report will tell you the answers. Simply by ordering and reading GMR Data’s new ‘Ophthalmic Drugs; Data, Analysis and Forecasts to 2024’ report, you can stay ahead of your competition. It really is that simple.

GMR Data forecasts that the global ophthalmic drugs market will reach $9.7bn by 2024. The US market growth will be slow compared to other markets predominantly due to major drug patent expiry and generic erosion. For example;

Xalabrands from Pfizer used for treatment of Glaucoma expired in the US in March 2011.
Azopt by Alcon used for treatment of Glaucoma expired in the US in October 2012.
Lumigan by Allergan used for treatment of Glaucoma expired in the US in 2013.
Restasis from Allergan used for treatment of Dry eye will expire in the US in May 2014.
Travatan by Alcon used for treatment of Glaucoma will expire in the US in 2014.
Combigan by Allergan used for treatment of Glaucoma will expire in the US in 2022.
Lucentis from Novartis used for treatment of Retinal Disorder will expire in the US in June 2020.

Restasis by Allergan is the market-leading drug in the ophthalmic market with sales of $1bn across 2013. Will it be able to see off the competition for the next 5 years? The next 10 years? This report tells you. With an assessment of the leading markets, such as the US, and EU, GMR Data examine how Germany and France are the largest EU markets and what % of the global market they make up. Which other countries contribute most? This report tells you in a concise, focused and easily accessible format.

But how will these country’s markets develop? This report will tell you – TODAY

Global incidences of AMD, Glaucoma and Diabetic Retinopathy are all set to increase dramatically across the forecast period of 2014-2024; this will have the knock-on effect of driving sales of key drugs for treatment i.e. Lucentis and Eylea, as well as driving R&D. How much is being spent on R&D – and which drugs are likely to see a return? And how quickly?

Which new drugs will we see in the ophthalmic market across 2014-2024?

In December 2013 Santen announced that Ikervis (Ciclosporin / Cyclokat) was filed to the EMA, in doing so the EMA will begin its regulatory process. Diquas, which was launched in 2010 by Santen Pharma in Japan, China and other Asian markets, and despite US trials being unsuccessful, is expected to gain approval in the EU early in our forecast period.

Other key ophthalmic drugs currently under taking trials include;

Sirolimus (By Santen, in Phase III US)
Tafluprost/Timolol maleate (By Santen, filed for NDA)
Catioprost (By Santen in Phase 2)

PLUS – In-depth country analysis – Discover which countries and regions will drive the ophthalmic drugs market to 2024?

Exclusive Industry sourced information, not available anywhere else

As well as primary and secondary research sources, GMR Data have interviewed leading ophthalmic specialists within big pharma, R&D, wholesalers, distributors, marketeers and key clinical organisations. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field – This information is not available anywhere else.

Browse complete Report on:

http://www.aarkstore.com/healthcare/67271/ophthalmic-drugs-data-analysis-and-forecasts

For More Related Market Research Reports click here: Pharmaceuticals & Healthcare Market Research Reports

About Aarkstore.Com

Contact Details:

Aarkstore – The Chinese Pharmaceuticals Market to 2024

Summary

The OTC drugs market in China was characterised by a late start, but fast growth, along with huge potential in comparison to that of the mature OTC markets in many western countries. Your company should be benefiting from this market access – and this is only the OTC market – what has the growth been throughout the whole Chinese pharma sector? This report will tell you.

China’s pharmaceutical sales growth is based on economic growth in the country: This has resulted in increased healthcare expenditure internally, and increased manufacture and export. Increasing urbanisation, disposable income, aging population, health education, lifestyle diseases and government investments and initiatives for healthcare infrastructure improvement have helped the market growth considerably. Have you captured enough of the Chinese market?

Annually, an average of $190 is spent for the treatment of diabetes, per patient, in China. By 2030, in China, diabetes is expected to cost Yuan 173.4bn ($28 bn) a year. China is expected to top the world’s diabetes tables both in terms of sheer numbers and population prevalence. This is true across a range of complaints and products types – your company must capture a segment of this market TODAY.

Anti-Counterfeiting and anti-corruption – How the Chinese market is changing

Counterfeit drugs are successfully introduced in to the lengthy and complicated delivery chain because of the highly fragmented nature of the market. A lack of regular inspections by any recognised drug enforcement / regulatory bodies, again due to the highly fragmented nature of production, allows counterfeit / poor quality drugs into the Chinese pharma market. Moreover, wide spread corruption also helps the distribution of counterfeit drugs. What are the Chinese regulators, and the global manufacturers doing to change this? Find out in this unique report.

Increased inward investment from multiple ‘Big Pharma’ companies has driven investment in R&D centres as well as opportunities for Chinese graduates. Many graduates are staying in China; those that have left now have jobs to return to. Are you producing enough of your products in China? Increase your profitability through this channel.

Domestically, increased levels of health insurance, increased health education, rising numbers of hospitals and increased per capita income have all driven the Chinese pharmaceutical market.

Increase in healthcare expenditure per capita, from $157in 2008 to $278 in 2011
Increasing income and population. The middle class population reached 400m in 2010 and is expected to reach 500m by 2015
In 2012, the central government alone invested CNY 24.3bn ($3.9bn) to improve health service infrastructure.
Key life style changes, which have accelerated the diseases such as obesity, diabetes, cardiovascular, chronic respiratory diseases
The over 65 population has increased to 9.1% of the total population in China in 2011 from 8.3% in 2008

This report also breaks down the market in terms of current drugs and products that occupy the Chinese market at present; examining the key prescription and OTC drugs that drive the Chinese market. In addition to this crucial information this report offers analysis and opinion on current R&D in the country alongside in depth analysis of the evolving, global inward investment.
Browse complete Report on:

http://www.aarkstore.com/healthcare/67269/the-chinese-pharmaceuticals-market

For More Related Market Research Reports click here: Pharmaceuticals & Healthcare Market Research Reports

About Aarkstore.Com

Contact Details:

Aarkstore – The Global Pre-Filled Syringe Market to 2024

Summary

The “Global Pre-filled Syringe Market 2014-2024” report analyses how this important sub-sector will continue to grow across the next decade. The report highlights key companies, geographies and products that we believe will deliver double digit growth across the next decade

Buy this report today and acquire analysis of the state of the pre-filled syringes market in 2014 and a market forecastfor the period 2014-2024. Market forecasts are also provided for global pre-filled syringes for glass and plastics on the global level (value and volume) as well as for the geographic regions of key pre-filled syringe types (value and volume).

The advantages that will drive the growth of pre-filled syringes include ease of administration, improved safety, reduced risk of contamination, elimination of medication errors, low incidence of needlestick injuries, accurate dosing and reduction in medical expenditure due to reduced visits to healthcare facilities.

When compared to standard injectables, the pre-filled syringes market is still evolving, and its use is slowly increasing. Developed countries have shown a strong adoption rate for pre-filled syringes whereas developing & ROW countries have often been slow in adopting this technology. During the forecast period, however, the adoption rate will witness a healthy growth in emerging markets, and will witness a growth rate above that of developed geographies such as the US and in Europe.

The market is highly consolidated and is currently dominated by key global players such as Abbott Labs, Becton Dickinson, Baxter, Nipro Corporation, Schott, Gerresheimer, West Pharmaceutical, Ypsomed, Bespak and Unilife Corporation. Other companies such as Haselmeier; Weigao Group, Nuova Ompi (Stevanato Group), Owen Mumford and Vetter Pharma are likely to foster innovation in the coming years.

The Global Pre-filled Syringe Market 2014-2024 report includes over 125 tables, charts and graphs quantifying and forecasting the market in detail. In addition, the report offers 14 profiles of the leading PFS companies in the market alongside 3 expert interviewees offering key insights into the state of the market currently and in the future;

Browse complete Report on:

http://www.aarkstore.com/healthcare/67350/the-global-pre-filled-syringe-market

For More Related Market Research Reports click here: Pharmaceuticals & Healthcare Market Research Reports

About Aarkstore.Com

Contact Details:

Aarkstore – Cloud Computing Development and Commercial Applications – Data, Analysis and Forecasts to 2019

Summary

Cloud computing continues to gain acceptance in business, enterprise and consumer markets. But can the momentum be sustained? Can current market prices remain? Will the infrastructure and security be satisfactory for the growing user base? With increased concerns over data ownership, will users remain satisfied with outsourced storage and access? We are now entering a stage of user acceptance, so can Cloud companies maintain their usage rates and stop churn? These are key questions as we enter the next phase of Cloud acceptance. This report will ensure you and your company are in the best position to take advantage of the key opportunities within the Cloud IT market.

– GMR Data predict that the cloud computing market will be worth $75bn this year, but what will it be next year? What about the following year, and in 2019? This report tells you.
– Which areas of the world will be key in cloud computing as the industry develops, seeks to maximize revenues and reduce costs? GMR Data will tell you.
– What are the key R&D pipelines and high growth potential in each industry and regional sector?

The 3 Key challenges that must be faced in the global cloud computing market include:

1. The cloud computing market has grown exponentially over the last 5 years. As companies and increasingly individuals and governments have begun or deployed this service for reasons primarily related to expenditure reduction, productivity, and efficiency, the cloud computing market has grown considerably – how has the market coped with this? Can the infrastructure hold up?

2. This increased market is directly linked to pricing and savings – can these pricing strategies be maintained? With the major IT players offering cloud services we can expect major competition, but does it ensure innovative services and value? With various pricing models based on subscription, consumption, advertising, and market-based, is your company achieving the best revenue streams or is your company operating within the best pricing format.

3. Key services that are proving particularly popular relate to data storage, backup and recovery, as well as customer relationship management models and user productivity suites. There is still space in the market for innovative services that drive expenditure reduction, productivity, and efficiency. What will they be, and who will get them to market first?

Through reading this report you will gain knowledge of the following:

a) Analysis of the state of the global cloud computing market in 2014 and a market forecast for the period 2014-2019.
b) Identify how the market operates and which companies are operating in the market, their current products and pipeline candidates
c) Discover how the global cloud market is evolving across the forecast period of 2014-2019 through the examination of global and regional benefits and challenges, particularly relating to political, economic, social, and technological factors
d) Read our interview with 2 key global authorities, as well as 2 new entrants, in the cloud computing market

Only by ordering this in-depth exclusive report will you have full access to the unique findings. This information is not available anywhere else. Find full details of these IT developments and services in this new GMR Data report.

Discover exactly what the industry leaders are doing TODAY –

Within GMR Data’s Cloud Computing Development and Commercial Application – Data, Analysis and Forecasts to 2019’ we analyse the key Cloud Computing and Services in the market today and how they will perform across the next 5 years.

Our study focuses on the revenues of the top cloud computing companies. With variable services and pricing models how will these key companies and services fare across the next five years? – ONLY THIS UNIQUE REPORT WILL TELL YOU

– IBM
– Microsoft
– Cisco
– Oracle
– EMC
– HP
– Alibaba
– Amazon Web Service (AWS)
– Google
– VMWare
– Salesforce
– Dropbox
– Box

PLUS – In-depth country analysis – Discover which countries and regions will see the greatest impact of cloud computing operation and infrastructure to 2023?
Browse complete Report on:

http://www.aarkstore.com/technology/67273/cloud-computing-development-and-commercial-applications-data-analysis-and-forecasts

For More Related Market Research Reports click here: Technology Market Research Reports

About Aarkstore.Com

Contact Details:

industryanalysisreports

Month: February 2015

Aarkstore – GRDSdata – Subscription to industry data from across more than 100 industries and 90 countries

Aarkstore – The Cancer Drugs & Treatments Market – Data, Analysis & Forecasts to 2023

Aarkstore – Ophthalmic Drugs; Data, Analysis and Forecasts to 2024

Aarkstore – The Chinese Pharmaceuticals Market to 2024

Aarkstore – The Global Pre-Filled Syringe Market to 2024